Purpose: To evaluate safety, efficacy, and stability of crosslinking (CLX) procedure as a method for keratoconus treatment in the I and II stage of disease.
Materials and methods:Twenty eyes of 15 patients (13 males, 2 females, average age 31 years) with keratoconus I stage (13 eyes) and II stage (2 eyes) (by Krumeich classification) were treated by CLX procedure, using riboflavin Medio Cross for standard CLX); riboflavin Medio Cross TE for transepithelial CLX was used to treat keratectasia after previous keratorefractive surgery; in all the cases UV CBM X linker (Vega, CSO) was used. The study included evaluation of uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA) pre-and postoperative, pachymetry (central cornea thickness) (Visante OCT, Zeiss) pre-and postoperative, total astigmatism pre-and postoperative, using keratotopography (Atlas, Zeiss). Diagnosis and analysis have been
Conclusion:Cross-linking indicated safety, stability, and efficacy for treatment of I and II stage keratoconus at the end of follow-up period. Cross-linking is not effective in the treatment of II and III stage of disease. Further study is required.